Survival in ursodeoxycholic acid-treated patients with biliary cirrhosis

Bonnand, AM; Poupon, R

doi:10.1016/s0016-5085(96)70051-3

Cited by 6 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treating transplantation patients as being censored on the date of transplantation has been disputed as violating the assumption of random censoring. The incorrect censoring occurs because patients who undergo transplantation are known to be at a higher risk of death than other patients (as discussed by Bonnand & Poupon, 1996) so censoring time cannot be considered independent of end-point. Independence is one of the underlying assumptions in the proportional hazards model-fitting procedure.…”

Section: Cross-validation Techniquesmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic systems and the natural history of cirrhosis

Μοσχανδρέα¹

View full text Add to dashboard Cite

HCC patients treated with octreotide versus controls…..…………. 3.3.3.HCC patients treated with long-acting stomatostatin versus historical controls………..………………………………………… 3.4. Patients with ascites……………………………………………… 3.5. Epidemiological survey ………..………………………………… 4. RESULTS………………………………………………………… 70 4.1. Survival analysis………………………………………………….. 70 4.1.1. Natural history of cirrhosis…………………….………………….. 70 A. Prognosis for compensated cirrhotics…………………………... 70 B. Prognosis for decompensated cirrhotics………………………... 84 C. HCC incidence rates…………………………………………… 88 4.1.2. Treatment of type C cirrhosis……………………….…………….. 91 4.1.3. UDCA treatment for PBC patients………………………………… 94 4.1.4. Natural history of HCC……………………………………………. 100 4.1.5.

show abstract

Section: Cross-validation Techniquesmentioning

confidence: 99%

“…This type of model could also be applied in the case of PBC data in which transplantation could be taken into account as an intermediate event (as mentioned by Bonnand & Poupon, 1996).…”

Section: Further Approaches To Model-fittingmentioning

confidence: 99%

Prognostic systems and the natural history of cirrhosis

Μοσχανδρέα¹

View full text Add to dashboard Cite

show abstract

Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis

et al. 2008

View full text Add to dashboard Cite

Biochemical response to ursodeoxycholic acid (UDCA) in patients with primary biliary cirrhosis (PBC) is variable. It has been recently proposed that an alkaline phosphatase (ALP) decline of more than 40% in baseline value or a normal level after 1 year of UDCA treatment (Barcelona criteria) could serve as a good marker of long-term prognosis. Our aim was to define the best efficient set of biochemistries able to identify UDCA-treated patients at risk of death or liver transplantation (

show abstract

Ten–Year Survival in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cirrhosis

et al. 1999

View full text Add to dashboard Cite

Ursodeoxycholic acid (UDCA) treatment has been shown to increase survival without orthotopic liver transplantation (OLT) in patients with primary biliary cirrhosis (PBC) at 4 years. Whether this beneficial effect was maintained over the long term remained to be established. In a large cohort of UDCA-treated patients with PBC, we aimed to determine the 10-year outcome of these patients using two endpoints: (1) survival without OLT, and (2) survival. The cohort was comprised of 225 patients with PBC treated with UDCA (13-15 mg/kg/d) monitored from the beginning of treatment until time of last follow-up, OLT, or death. Because of the absence of a control group, survival without OLT was compared with survival predicted by the Mayo model (first 7 years), and observed 10-year survival with an estimation of survival of a standardized control cohort of the French population. Observed survival without OLT of UDCAtreated patients was significantly higher (P F .04) than survival predicted by the Mayo model. Observed survival was significantly lower (P F .01) than survival predicted from the French population. Observed survival of noncirrhotic patients was not different (P G .9) from that of the French control population but survival of cirrhotic patients was significantly lower (P F .0001). Twenty-two patients died; 13 patients died of hepatic causes and 4 patients died after OLT. In conclusion, survival without OLT among patients treated with UDCA for PBC is higher than that of untreated patients, as predicted by the Mayo model. Tenyear survival among UDCA-treated patients is slightly lower than that of an age-and sex-matched general population, the difference mainly being explained by mortality among cirrhotic patients. (HEPATOLOGY 1999; 29:1668-1671.)

show abstract

Survival in ursodeoxycholic acid-treated patients with biliary cirrhosis

Cited by 6 publications

References 0 publications

Prognostic systems and the natural history of cirrhosis

Prognostic systems and the natural history of cirrhosis

Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis

Ten–Year Survival in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cirrhosis

Contact Info

Product

Resources

About